Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 27:4:19.
doi: 10.3389/fonc.2014.00019. eCollection 2014.

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

Melissa Burgess  1 , Shannon Puhalla  1
Affiliations
Review

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

Melissa Burgess et al. Front Oncol. .

Abstract

No longer is histology solely predictive of cancer treatment and outcome. There is an increasing influence of tumor genomic characteristics on therapeutic options. Both breast and ovarian cancers are at higher risk of development in patients with BRCA 1/2-germline mutations. Recent data from The Cancer Genome Atlas and others have shown a number of genomic similarities between triple negative breast cancers (TNBCs) and ovarian cancers. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in hereditary BRCA 1/2-mutated and sporadic breast and ovarian cancers. In this review, we will summarize the current literature regarding the genomic and phenotypic similarities between BRCA 1/2-mutation related cancers, sporadic TNBCs, and sporadic ovarian cancers. We will also review Phase I, II, and III data using PARP inhibitors for these malignancies and compare and contrast the results with respect to histology.

Keywords: BRCA 1/2-mutations; BRCAness; PARP inhibitor; breast cancer; ovarian cancer; reversion mutations.

PubMed Disclaimer

References

    1. D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer (2003) 3:23–3410.1038/nrc970 - DOI - PubMed
    1. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res (2003) 31(19):5526–3310.1093/nar/gkg761 - DOI - PMC - PubMed
    1. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature (1992) 356:356–810.1038/356356a0 - DOI - PubMed
    1. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol (1998) 18(6):3563–71 - PMC - PubMed
    1. Strom CE, Johansson F, Uhlen M, Szigyarto CA, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res (2011) 39(8):3166–7510.1093/nar/gkq1241 - DOI - PMC - PubMed

LinkOut - more resources